During Thursday’s Afternoon trade, Shares of Capnia, Inc. (NASDAQ:CAPN), skyrocketed 93.25% to $3.15.
Capnia, Inc. (CAPN), focused on the development and commercialization of novel products based on its proprietary technologies for precision metering of gas flow, declared financial results for the second quarter ended June 30, 2015.
Recent Developments and Forthcoming Milestones
CoSense
Executing CoSense Commercial Rollout — During the second quarter, Capnia strengthened its commercial sales team with the appointment of Chief Commercial Officer, Edward Ebbers. This neonatology-focused team is targeting 400 of the top U.S. hospitals based on number of newborn births each year, with the aim of maximizing initial sales of the CoSense device and rapidly growing recurring revenues from sales of per-test consumables. The commercial sales team has profiled and identified key accounts nationwide and the Company is in talk aboutions with several healthcare institutions.
Developing Sickle Cell Disease (SCD) Screening in Developing Countries — In April, Capnia declared it was awarded a Small Business Innovation Research (SBIR) Phase I grant for $220,000 by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This grant will be used to assist fund the development of a modified CoSense device that is suitable for field use in developing countries with high prevalence of SCD.
Capnia, Inc. develops diagnostics and therapeutics based on its proprietary technology for precision metering of gas flow primarily in the United States.
Shares of xG Technology, Inc. (NASDAQ:XGTI), inclined 54.72% to $2.46, during its current trading session.
xG Technology, declared that its 1-for-10 reverse split of its common stock became effective at 5:00 p.m. Eastern Time on Friday, July 17, 2015, and the Common Stock will open for trading on July 20, 2015 on a post-split basis.
In connection with the Reverse Stock Split, the CUSIP number for the Common Stock has been changed to 98372A 507.
xG Technology, Inc. develops communications technologies for wireless networks worldwide. The company’s intellectual property is embedded in proprietary software algorithms designed to offer cognitive interference mitigation and spectrum access solutions to organizations in a various industries, counting national defense and rural broadband. Its products comprise xMax, a mobile voice over Internet protocol (VoIP) and broadband data system that utilizes an end-to-end Internet protocol (IP) system architecture, which incorporates OFDM and multiple in multiple out and orthogonal frequency-division multiple to enhance interference tolerance, allow mobility, and improve resistance to fading.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), surged 22.94%, and is now trading at $5.03.
Eleven Biotherapeutics stated financial results for the second quarter ended June 30, 2015, and recent business highlights.
Second Quarter and Recent Business Highlights:
- Initiated a Phase 3 study of EBI-005 for the treatment of moderate to severe allergic conjunctivitis patients suffering from the late-phase inflammatory response. EBI-005 offers the potential to mediate this late-phase allergic response by blocking the interleukin-1 (IL-1) receptor, believed to play a key role in ocular surface disease, while also exhibiting an acceptable safety and tolerability profile to date. Top-line data from this study is predictable in the first quarter of 2016. The initiation of this Phase 3 study follows completion of a Phase 2 clinical trial in which EBI-005 achieved statistically noteworthy improvements in ocular itching, ocular tearing and nasal symptoms in the late phase allergen response in moderate to severe allergic conjunctivitis patients following allergen exposure in a modified direct conjunctival allergen challenge (CAPT) model.
- Presented clinical data for EBI-005 for the treatment of allergic conjunctivitis at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting. EBI-005 showed clinically relevant, statistically noteworthy improvements in multiple endpoints counting ocular itching, ocular tearing and nasal symptoms associated with the late phase allergen response. These data further support the important role of IL-1 as a key target for ocular surface inflammation associated with allergic conjunctivitis, a mechanistically different disease from dry eye disease due to its single, central mechanism of allergen stimulation as opposed to the many diverse causes of ocular surface inflammation in dry eye disease.
Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States.
Finally, One Horizon Group, Inc. (NASDAQ:OHGI), surged 21.73%, and is now trading at $1.68.
One Horizon Group declared that it has signed a contract to be the exclusive supplier of Voice over IP services to KeyIdea Information Technology Co., Ltd (“KeyIdea”), a renowned manufacturer of satellite equipment in China. KeyIdea will commence operations of their new maritime satellite service in the fourth quarter of 2015 and will supply their crew-calling services exclusively using the Aishuo platform.
One Horizon further expands its subscriber base through the high Revenue Per User (“RPU”) crew-calling distribution channels by providing the newest entrant in the Chinese satellite operator space with a new recurring revenue stream for voice and messaging on top of the traditional equipment sales and satellite airtime rental revenues. KeyIdea will purchase pre-paid calling cards from Aishuo and resell to the crew on-board. Their fleets or crew members will have the availability to top-up online using the App. The calls will be carried through Aishuo’s Public Switched Telephone Network (“PSTN”) in China and billed to the crew on a pay-as-you-go basis.
One Horizon’s optimized technology was selected from a shortlist of platforms evaluated by KeyIdea as its unique low bandwidth usage coupled with high voice quality makes it an ideal solution for smaller capacity Internet connections such as those found on 2G, 3G and satellite. The Company’s track record of successful maritime deployments with Singapore Telecommunications (“Singtel”) and Smart Communications in the Philippines (“Smart”) were key reference deployments over satellite that KeyIdea considered as part of their selection process.
One Horizon Group, Inc., through its auxiliaries, develops and licenses software solutions to telecommunications operators in Europe, Asia, the Russian Federation, and the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
